Satellos Bioscience Shareholders Elect Two New Board Members

Article content
TORONTO — Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (' Satellos ' or the ' Company '), a biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, today announced the election of Iris Loew-Friedrich, M.D., Ph.D., and Selwyn Ho, MBBS, to its Board of Directors.
Article content
'I am so excited to welcome Dr. Loew-Friedrich and Dr. Ho to our Board at this pivotal time,' said Frank Gleeson, Satellos co-founder and CEO. 'We believe their deep expertise in global clinical and commercial development will be invaluable to Satellos as we advance SAT-3247 and realize our technology's transformative potential for the treatment of people living with Duchenne muscular dystrophy and other degenerative conditions. We look forward to drawing on their proven expertise in positioning Satellos for future partnerships and development strategies focused on delivering optimal value for shareholders.'
Article content
A highly accomplished biotech and pharmaceutical executive, Dr. Loew-Friedrich is recognized as the senior clinical leader who shaped UCB into a global powerhouse in neurology and immunology. Serving as executive vice president and chief medical officer until 2024, she led UCB's worldwide development and regulatory strategy for over two decades, overseeing the global approvals of multiple blockbuster therapies, including Cimzia, Briviact, Evenity, Rystiggo, Zilbrysq, and Bimzelx. Her leadership was instrumental in advancing both common and rare disease treatments, with a deep and sustained commitment to improving outcomes for underserved patient populations. Prior to UCB, Loew-Friedrich held senior R&D roles at Schwarz Pharma, BASF Pharma, and Hoechst/Aventis, where she contributed to the development and success of market-leading drugs such as Humira, Arava, Actonel, Vimpat, and Neupro.
Article content
Dr. Ho is a seasoned pharmaceutical and biotech executive with broad leadership experience across commercial strategy, business development, financing, and board governance. He has held senior roles at global companies including Dermira (Eli Lilly), UCB, Allergan (AbbVie), Novartis, and AstraZeneca, with expertise spanning ophthalmology, immunology, oncology, and dermatology. As CEO of Medigene AG, he led a strategic transformation and established and extended key partnerships with BioNTech, Regeneron, WuXi Biologics and EpimAb Biotherapeutics. Previously, as EVP & chief business officer at Connect Biopharma, he was instrumental in raising over $350 million through IPO and private funding. He also serves on the boards of Antennova Inc. and Peptomyc S.L., and as executive-in-residence at New Rhein Healthcare Investors.
Article content
As part of the Annual General Meeting, Rima Al-awar, Ph.D., William Jarosz, J.D., and William McVicar, Ph.D., did not stand for reelection.
Article content
'I want to personally thank Rima, Bill and Bill for their dedicated service, thoughtful leadership and support,' said Gleeson. 'Their guidance helped position Satellos for continued progress, and we wish them all the best in their future endeavors.'
Article content
About Satellos Bioscience Inc.
Article content
Satellos is a clinical-stage drug development company focused on restoring natural muscle repair and regeneration in degenerative muscle diseases. Through its research, Satellos has developed SAT-3247, a first-of-its-kind, orally administered small molecule drug designed to address deficits in muscle repair and regeneration. SAT-3247 targets AAK1, a key protein that Satellos has identified as capable of replacing the signal normally provided by dystrophin in muscle stem cells to effect repair and regeneration. By restoring this missing dystrophin signal in DMD, SAT-3247 enables muscle stem cells to divide properly and more efficiently, promoting natural muscle repair and regeneration. SAT-3247 is currently in clinical development as a potential disease-modifying treatment initially for DMD. Satellos also is leveraging its proprietary discovery platform MyoReGenX™ to identify additional muscle diseases or injury conditions where restoring muscle repair and regeneration may have therapeutic benefit and represent future clinical development opportunities. For more information, visit
Article content
.
Article content
This press release includes forward-looking information or forward-looking statements within the meaning of applicable securities laws regarding Satellos and its business, which may include, but are not limited to, statements regarding the potential for SAT-3247 to represent a disease modifying approach to the therapeutic treatment of people living with Duchenne; anticipated benefits to patients from a small molecule treatment for Duchenne; the advancement SAT-3247 through clinical trials; the pharmacodynamic properties and mechanism-of-action of SAT-3247; the potential of our approach in other degenerative muscle diseases; its/their prospective impact on Duchenne patients, patients with other degenerative muscle disease or muscle injury or trauma, and on muscle regeneration generally; and Satellos' technologies and drug development plans. All statements that are, or information which is, not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, occurrences or developments, are 'forward-looking information or statements.' Often but not always, forward-looking information or statements can be identified by the use of words such as 'shall', 'intends', 'believe', 'plan', 'expect', 'intend', 'estimate', 'anticipate', 'potential', 'prospective' , 'assert' or any variations (including negative or plural variations) of such words and phrases, or state that certain actions, events or results 'may', 'might', 'can', 'could', 'would' or 'will' be taken, occur, lead to, result in, or, be achieved. Such statements are based on the current expectations and views of future events of the management of the Company. They are based on assumptions and subject to risks and uncertainties. Although management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release, may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including, without limitation, risks relating to the pharmaceutical and bioscience industry (including the risks associated with preclinical and clinical trials and regulatory approvals), and the research and development of therapeutics, the results of preclinical and clinical trials, general market conditions and equity markets, economic factors and management's ability to manage and to operate the business of the Company generally, including inflation and the costs of operating a biopharma business, and those risks listed in the 'Risk Factors' section of Satellos' Annual Information Form dated March 26, 2025 (which is located on Satellos' profile at
Article content
www.sedarplus.ca
Article content
). Although Satellos has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Satellos does not undertake any obligation to publicly update or revise any forward-looking statement, whether resulting from new information, future events, or otherwise.
Article content
Article content
Article content
Article content
Article content
Contacts
Article content
Investors:
Article content
Liz Williams, CFO,
Article content
Article content

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

CBC

10 minutes ago

• CBC

Canada Transport Minister Freeland slams B.C. Ferries deal with Chinese company

B.C. Ferries has drawn the ire of federal Transportation Minister Chrystia Freeland for its decision to contract a Chinese state-owned shipyard to build four new vessels for its passenger fleet. Freeland also expressed concerns about security risks related to the contract. In a letter to B.C.'s Transportation Minister Mike Farnworth released Friday afternoon, Freeland expressed her "great consternation and disappointment" with the ferry operator. "I am dismayed that B.C. Ferries would select a Chinese state-owned shipyard to build new ferries in the current geopolitical context," Freeland wrote. Earlier this month, B.C. Ferries said the winning bidder on the contract is China Merchants Industry Weihai Shipyards. No Canadian companies bid on the ships, according to B.C. Ferries. But Freeland said, given the value of the contract and the amount of taxpayer money provided to B.C. Ferries' operations, she would have expected Canadian companies to be involved in the bid process. "I am surprised that B.C. Ferries does not appear to have been mandated to require an appropriate level of Canadian content in the procurement or the involvement of the Canadian marine industry," she wrote. Freeland said China has imposed "unjustified tariffs" on Canadian goods, including 100 per cent tariffs on canola oil, meal and pea imports and a 25 per cent duty on Canadian aquatic products and pork. She asked her provincial counterpart to share what it will do to address potential threats to security, including cybersecurity, and determine how B.C. Ferries will lessen "the risks that vessel maintenance and spare parts may pose." "I would like your assurance that B.C. Ferries conducted a robust risk assessment, and I expect them to engage with the relevant provincial and federal security agencies and departments to mitigate any security risk." WATCH | Farnworth worries about B.C. Ferries contract: Transportation minister concerned over B.C. Ferries' construction deal with Chinese shipyard 9 days ago Duration 2:06 Freeland said the federal government has a long record of providing financial support to B.C. Ferries, including a federal subsidy of $37.8 million in 2025-26 dating back to a 1977 agreement. The letter went on to say the Canada Infrastructure Bank is providing the ferry operator with a $75-million loan to finance the purchase of four zero-emission ferries and install charging infrastructure Freeland asked Farnworth to confirm "with utmost certainty" that no federal funding would be used to acquire the new ferries. In an emailed statement late Friday, Farnworth said he has spoken to Freeland about the need to bolster the province's shipbuilding sector. "B.C. has the skilled labour — a partnership with the federal government, provincial governments, and industry is essential for Canadian shipyards to expand physical capacity to build commercial vessels on both coasts," he said. The B.C. Ministry of Transportation said it is reviewing Freeland's letter. B.C. Ferries' response Jeff Groot, executive director of communications with B.C. Ferries, said Weihai Shipyards was selected following a rigorous and transparent procurement process. "It was the strongest bid by a significant margin," he said in an emailed statement. Groot said Canadian companies have acquired around 100 vessels built at Chinese shipyards over the last decade. "Globally, only a few shipyards have the capacity to deliver complex passenger ferries on the timelines and budgets required." Groot said B.C. Ferries has been working with Transport Canada since before the contract was signed, and with Public Safety Canada on safety and security issues. "Also, sensitive systems will be sourced separately and independently certified before the vessels enter service. B.C. Ferries intends that all of our IT networks will be procured from within Canada and installed on the ship by B.C. Ferries' own personnel," Groot said. He added a full-time B.C. Ferries oversight team will be on site at the shipyard.

CTV News

an hour ago

• CTV News

Tensions high in Village of Anmore as controversial development heads to public hearing

On Monday, mayor and council in the Village of Anmore will hold a public hearing on a large-scale, multi-family development that could more than double the population of the tiny enclave on the shores of Indian Arm over the next 20 years. The development called Anmore South would add 1,750 units of housing– comprised of condo buildings, townhomes and duplexes – on a large plot of forested land in the centre of the village that is owned by Icona Properties. 'Right now, Anmore is all single-family homes with a couple of duplexes, but basically single-family homes and one corner store, so not really commercial,' said Greg Moore, the former mayor of Port Coquitlam, who is now CEO of Icona Properties. 'This helps to bring jobs and create that complete community for the Village of Anmore.' There is fierce opposition to the project, evidenced by signs on public spaces all over Anmore calling on mayor and council to scrap the development. 'It's too dense for a rural area,' said longtime Anmore resident Leslie Hannigan. 'The reason we moved here is because it's quiet. We aren't part of the urban containment boundary, so we're not in those rules of having to make everything really, really dense.' She argues the village's infrastructure is not meant for a large population, and bristles at the suggestion homeowners in Anmore are NIMBYs opposed to any new development. 'We could have done a really nice thing within our rural designation with townhomes, with cluster homes for seniors, there's laneway homes. There's all kinds of things without having to be this thick, dense area that developers seem to be pushing into all these municipalities,' Hannigan said. Anmore Mayor John McEwen says some in his community are opposed to any kind of change to the largely single-family home village, where the average assessed value is a little over $2,500,000. 'So, (it's) tough for young families to get in when you have such a high assessment,' said McEwen. 'And it's starting to show in our elementary school. Enrolment is a little over 100, where it used to be well over 200.' The mayor says the debate over adding condos and townhomes in Anmore has gotten nasty, with many signs targeting mayor and council, and online discourse that he calls disturbing. 'The word that has troubled me the most to my core is when I hear, 'We don't want that type of people here.' And that really, really bothers me,' said McEwen. 'I look at a diverse municipality that I want, I want it to be welcome to everybody.' Hannigan says she has never heard comments like that among Anmore residents. 'We welcome everyone,' she said. 'Nobody says we don't want these people in here. It's all about preserve the trees, keep us rural, small homes that are connected. I mean, this is again just a frustrating spin when they say that we're NIMBYs and we don't want this. That's wrong.' If mayor and council vote in favour of Anmore South on Monday, the developer still has to get Metro Vancouver to change the village's rural zoning designation in order to start construction on the project. 'If everything went yes votes all the way along the path, we probably wouldn't see a shovel in the ground for at least two years. And then at that point, it's going to be another 20 years as this community comes together,' said Moore. 'So there is lots of opportunity to continue to engage the community.' Right now, it's a community divided: remain a small village, or open the door to big-city density.

National Post

2 hours ago

• National Post

Transportation Minister Chrystia Freeland 'dismayed' about BC Ferries' contract with Chinese shipyard

VICTORIA — Federal Transport Minister Chrystia Freeland says she is 'dismayed' that BC Ferries has contracted a Chinese state-owned shipyard to build four new vessels in the current geopolitical context that includes 'unjustified' tariffs on Canada. Article content Freeland says in a letter sent to provincial Transportation Minister Mike Farnworth that she expects BC Ferries to inform her about all measures that it plans to take to 'mitigate any security risks,' including cybersecurity problems that might arise from the decision. Article content Article content BC Ferries announced earlier this month that it has contracted China Merchants Industry Weihai Shipyards to build four new major vessels following a five-year-long procurement process that did not include a Canadian bid. Article content Article content Freeland adds she is 'surprised' that BC Ferries does not have a mandate for an 'appropriate level' of Canadian content in the procurement given the value of the contract, although the dollar figure hasn't been made public. Article content BC Ferries says in a statement that the Chinese bid was 'the strongest bid by a significant margin' and that security is a 'top priority,' adding that all sensitive systems will be sourced separately and independently certified before the vessels enter service. Article content